BIOA (BioAge Labs, Inc.) Short-Term Debt to Capital

Corporate company logo of BioAge Labs, Inc. (BIOA)

The market dynamics of BioAge Labs, Inc. (BIOA) securities on the GURU.Markets platform, where the indicator stands at 0.00, illustrate the company's efforts to develop anti-obesity treatments by studying aging processes using AI. Innovative biomarkers provide a powerful moat against competitors during testing. However, geopolitical instability and disruptions in biomaterial supplies seriously hinder the conduct of global research.

Ratio of Short-Term Indebtedness to Capital: BioAge Labs Inc. (BIOA) for 09/27/2024 - 10/30/2026

Analytical breakdowns for BioAge Labs, Inc.

- stock quotes and analyst forecast:
Stock Price BioAge Labs Inc.|BIOA - Fair Value Consensus
- business market valuation indicators:
Market Capitalization BioAge Labs|BIOA - Enterprise Value
- book capitalization information:
Net Assets per Single Share BioAge Labs, Inc.|BIOA - Accounting Value of Company|Market Value to Book Value Ratio bioagelabs.com|BIOA - Cumulative Company Assets
- company liabilities and liquidity data:
Total Debt to Capital BioAge Labs, Inc.|BIOA - Long-Term Debt to Capital|Short-Term Debt to Equity Ratio BioAge|BIOA - Aggregate Debt Obligations|Debt to Book Capitalization Ratio BioAge Labs|BIOA - Company Long-Term Liabilities|Company Short-Term Debts BioAge Labs, Inc.|Quick Liquidity Indicator bioagelabs.com
- company profitability and valuation multiples indicators:
BIOA - Profit After Payment of Taxes
Fundamental valuation:BIOA BioAge Labs Inc.
Brand item of BioAge Labs

This ratio compares the volume of liabilities with a maturity of up to one year against total equity, measuring the current debt load relative to the asset base. For BioAge Labs, Inc. (BIOA), low reliance on short-term loans confirms a resilient balance sheet supported by patents and partnerships with pharma behemoths. Analyzing the short-term debt-to-equity ratio allows for an assessment of liquidity risk. The stability of this metric guarantees financial maturity and the potential to act as a cash generator for free cash flow.

Competitors of BioAge Labs, Inc.

Short-Term Debt to Capital ASND|MDGL (Madrigal Corp) - Ratio of Short-Term Indebtedness to Capital|Short-Term Debt to Capital CORT (Corcept Therapeutics)|Short-Term Debt to Capital rhythmtx.com RYTM|AKRO - Short-Term Debt to Equity|Ratio of Short-Term Indebtedness to Capital MTSR (Metsera, Inc.)|MoonLake Pharma (MLTX) - Short-Term Debt to Equity|Short-Term Debt to Equity Ratio Crinetics Corp|NAMS (NewAmsterdam Pharma) - Short-Term Debt to Capital|Short-Term Debt to Capital soleno.life|Short-Term Debt to Equity Ratio FOLD (Amicus Therapeutics, Inc.)|ETNB (89bio Inc) - Ratio of Short-Term Indebtedness to Capital|Short-Term Debt to Equity Agios Pharmaceuticals Inc AGIO|GPCR - Short-Term Debt to Equity Ratio|MiMedx Group, Inc. - Short-Term Debt to Capital|Current Liabilities to Capital rezolutebio.com|LXRX (Lexicon Pharmaceuticals, Inc.) - Short-Term Debt to Equity Ratio|MBX: Short-Term Loans to Capital Ratio|ALT (Altimmune Corp) - Short-Term Debt to Capital|Short-Term Debt to Capital Aardvark Pharma|Short-Term Debt to Capital SGMT|Short-Term Debt to Equity BMEA (biomeafusion.com)|Short-Term Debt to Equity Quince Therapeutics, Inc. QNCX|Fractyl Health Inc. (GUTS) - Current Liabilities to Capital|VTVT - Short-Term Debt to Equity|ATPC: Short-Term Debt to Equity|PLUR: Short-Term Debt to Capital|SYBX - Short-Term Debt to Capital Coefficient|Short-Term Debt to Equity Lipocine|Matinas BioPharma Holdings Inc. (MTNB) - Short-Term Debt to Capital Coefficient|Short-Term Debt to Equity Spruce Biosciences (SPRB)|Short-Term Debt to Equity Ratio Galecto Corporation GLTO|Short-Term Debt to Capital CTCX (Carmell Corporation)|lumos-pharma.com - Short-Term Debt to Equity|Organovo - Short-Term Debt to Capital|Short-Term Debt to Capital Coefficient Radius Recycling Inc. RDUS